Compare McKesson Corporation (MCK) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs ProShares Ultra Gold ETF — how do they compare? McKesson Corporation trades at $824.07 (market cap $97.35B), while ProShares Ultra Gold ETF trades at $44.77. The key difference: McKesson Corporation pays a 0.39% dividend while ProShares Ultra Gold ETF pays none, and McKesson Corporation is trading nearer its 52-week high, ProShares Ultra Gold ETF nearer its low. Which is the better fit depends on your goals.
| MCK | UGL | |
|---|---|---|
Market Cap | $97.35B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $995.69 | $85.62 |
52-Week Low | $659.01 | $33.59 |
Enterprise Value | $101.98B | — |
Dividend Yield | 0.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
UGL, the ProShares Ultra Gold ETF, trades at $43.39, down 0.41% amid bearish technical signals. The leveraged ETF faces pressure from higher interest rate expectations and a stronger dollar, with gold struggling to hold the $4,000 support level. Recent news highlights mixed sentiment, with Wall Street bearish on near-term gold prospects but long-term structural drivers like central bank buying remaining intact.
Outlook remains cautious as UGL's performance hinges on gold price volatility and Fed policy. Risks include leveraged decay and macroeconomic shifts, while opportunities exist if gold resumes its bull trend. Investors should weigh the ETF's high sensitivity to daily gold moves against current bearish technical and sentiment indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
